tirzepatide kidney damage (Zepbound) showed improved function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide improves kidney outcomes in

68 year old male with severe sebaceous hyperplasia affecting his entire face, causing persistent redness and oily skin

In T2DM patients, lixisenatide reduced activation in brain areas including the hypothalamus, temporal lobar regions, lateral ventricle, and cortical areas in obese individuals in contrast to lean T2DM individuals, who showed increased activation in the areas [38]

Afterwards, Galen (129-c B activation and neutrophil apoptosis during active and resolved inflammation

Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases

AfA: Writingoriginal draft, Writingreview and editing